Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

NCT03661047 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03661047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03661047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2019
Completion date
November 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer